Department of Paediatric Oncology and Haematology, Charité-Universitätsmedizin, Berlin, Germany.
Bone Marrow Transplant. 2012 Feb;47(2):271-6. doi: 10.1038/bmt.2011.78. Epub 2011 Apr 11.
Infertility is a major late effect in patients receiving haematopoietic stem cell transplantation (HSCT). The aim of this study was to determine the proportion of patients having fertility impairment after allogeneic HSCT in childhood/adolescence and to identify the potential risk factors. Treatment and fertility data of paediatric patients with malignant and non-malignant diseases treated with allogeneic HSCT between 2000 and 2005 were collected from seven European centres. Data were obtained for 138 female and 206 male patients after a median follow-up of 6 years (range 3-12). The patients' median age was 13 years (range 4-28) at the time of HSCT and 19 (range 12-35) years at the time of the enquiry. Seven children were born to the overall group, all at term and healthy. Fertility impairment was suspected in 69% males and 83% females. Start of treatment at age 13 years was a risk factor in females (odds ratio (OR) 4.7; 95% confidence interval (CI), 1.5 to 14.9), whereas pre-pubertal therapy was a risk factor in males (OR 0.4; 95% CI, 0.2 to 0.8). The major treatment-related risk factors were BU in females (OR 47.4; 95% CI, 5.4 to 418.1) and TBI in males (OR 7.7; 95% CI, 2.3 to 25.4). In light of the significant proportion of HSCT patients reviewed with impaired fertility, fertility conservation procedures should be considered for all patients undergoing HSCT, particularly those receiving TBI or BU-based preparative regimens.
在接受造血干细胞移植 (HSCT) 的患者中,不孕是一个主要的晚期效应。本研究的目的是确定儿童/青少年时期接受异基因 HSCT 后生育受损的患者比例,并确定潜在的危险因素。从 2000 年至 2005 年,七个欧洲中心收集了患有恶性和非恶性疾病的儿科患者接受异基因 HSCT 的治疗和生育数据。在中位随访 6 年后(范围 3-12 年)获得了 138 名女性和 206 名男性患者的数据。HSCT 时患者的中位年龄为 13 岁(范围 4-28 岁),询问时的年龄为 19 岁(范围 12-35 岁)。整体组中有 7 名儿童出生,均足月且健康。怀疑有 69%的男性和 83%的女性生育受损。在女性中,治疗开始年龄为 13 岁(优势比 (OR) 4.7;95%置信区间 (CI),1.5 至 14.9)是一个危险因素,而青春期前治疗是男性的一个危险因素(OR 0.4;95%CI,0.2 至 0.8)。主要的治疗相关危险因素是女性中的 BU(OR 47.4;95%CI,5.4 至 418.1)和男性中的 TBI(OR 7.7;95%CI,2.3 至 25.4)。鉴于大量接受 HSCT 治疗的患者生育受损,应考虑对所有接受 HSCT 的患者进行生育保护程序,特别是那些接受 TBI 或基于 BU 的预处理方案的患者。